...
首页> 外文期刊>Drug Design, Development and Therapy >Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations
【24h】

Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations

机译:基于真实世界和实证评估的舒序宁注射液上市后安全性重新评估

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Aim: To evaluate the factors influencing suspected hypersensitivity and adverse systemic reactions after Shuxuening injection and to provide innovative ideas and methods for the reevaluation of post-marketing safety of Shuxuening. Methods: This study used a prospective, nested case–control study design, combined with a prescription sequence analysis design method. It classified patients who exhibited trigger signals after administration of Shuxuening injection as suspected allergic patients and made comparisons with patients who did not report adverse effects to calculate the correlation between relevant risk factors and suspected allergic reactions. Randomized controlled studies and cohort studies of the adverse drug reaction (ADR) of Shuxuening were performed using a computer database. Data retrieval was carried out by the foundation governing the individual database. Meta-analysis was performed by using R3.2.3 software to evaluate the ADRs of Shuxuening. Results: The results of real-world study showed that administration of Shuxuening in combination with potassium aspartate and magnesium, atorvastatin calcium, Shengmai injection, pantoprazole sodium, or high-dose medication was a risk factor for suspected allergic reactions. Meta-analysis showed that the incidence of adverse events was 5.84% (95% CI 0.0499; 0.0674), and serious adverse reaction rate was 4.36% (95% CI 0.0188; 0.0760) when Shuxuening was used in combination with these drugs. The incidence of allergic reaction was also influenced by the vehicle, duration of treatment, single dose, and indicated vs off-label use. Conclusion: Risk factors for adverse reaction following the use of Shuxuening injection in patients are associated with a single dose, vehicle, type of disease, and combination with potassium aspartate, atorvastatin calcium, Shengmai injection, injection with pantoprazole sodium, and other drugs. Physicians should be careful to follow guidelines when administering this drug. We further propose that the unique methodology used in this study may be useful for reevaluation of the safety of other traditional Chinese medicines.
机译:目的:评估舒序宁注射液后可疑的超敏反应和全身不良反应的影响因素,为重新评估舒序宁的上市后安全性提供创新思路和方法。方法:本研究采用前瞻性,嵌套式病例对照研究设计,并结合处方序列分析设计方法。该研究将舒序宁注射液给药后出现触发信号的患者归类为疑似过敏患者,并与未报告不良反应的患者进行比较,以计算相关危险因素与疑似过敏反应之间的相关性。舒雪宁药物不良反应(ADR)的随机对照研究和队列研究使用计算机数据库进行。数据检索由管理单个数据库的基金会执行。使用R3.2.3软件进行Meta分析,以评估舒序宁的ADR。结果:现实世界的研究结果表明,舒血宁与天冬氨酸钾和镁,阿托伐他汀钙,生脉注射液,pan托拉唑钠或大剂量药物合用是可疑过敏反应的危险因素。荟萃分析显示,舒舒宁与这些药物合用时,不良事件的发生率为5.84%(95%CI 0.0499; 0.0674),严重不良反应发生率为4.36%(95%CI 0.0188; 0.0760)。过敏反应的发生率还受媒介物,治疗持续时间,单次剂量以及指示使用与非标记使用的影响。结论:舒序宁注射液引起患者不良反应的危险因素与单剂量,媒介物,疾病类型以及天冬氨酸钾,阿托伐他汀钙,生脉注射液,pan托拉唑钠注射液及其他药物联合使用有关。医师在服用该药物时应注意遵循指导原则。我们进一步建议,本研究中使用的独特方法学可能有助于重新评估其他中药的安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号